Symbols / EBS
EBS Chart
About
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 586.33M |
| Enterprise Value | 1.00B | Income | 75.90M | Sales | 788.90M |
| Book/sh | 11.05 | Cash/sh | 4.67 | Dividend Yield | — |
| Payout | 0.00% | Employees | 900 | IPO | — |
| P/E | 8.33 | Forward P/E | 3.68 | PEG | — |
| P/S | 0.74 | P/B | 0.99 | P/C | — |
| EV/EBITDA | 4.55 | EV/Sales | 1.27 | Quick Ratio | 2.89 |
| Current Ratio | 5.76 | Debt/Eq | 115.19 | LT Debt/Eq | — |
| EPS (ttm) | 1.32 | EPS next Y | 2.99 | EPS Growth | -55.80% |
| Revenue Growth | -21.30% | Earnings | 2026-02-26 | ROA | 5.27% |
| ROE | 13.91% | ROIC | — | Gross Margin | 48.71% |
| Oper. Margin | 37.78% | Profit Margin | 9.62% | Shs Outstand | 52.52M |
| Shs Float | 47.49M | Short Float | 16.59% | Short Ratio | 9.28 |
| Short Interest | — | 52W High | 14.06 | 52W Low | 4.02 |
| Beta | 2.37 | Avg Volume | 805.07K | Volume | 630.10K |
| Target Price | $13.50 | Recom | None | Prev Close | $10.95 |
| Price | $10.99 | Change | 0.37% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.50
Mean price target
2. Current target
$10.96
Latest analyst target
3. DCF / Fair value
$37.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.96
Low
$12.00
High
$15.00
Mean
$13.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-01-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-30 | init | HC Wainwright & Co. | — → Buy | $15 |
| 2024-11-07 | main | Benchmark | Buy → Buy | $12 |
| 2024-09-13 | reit | Rodman & Renshaw | Buy → Buy | $16 |
| 2024-08-22 | init | Rodman & Renshaw | — → Buy | $16 |
| 2024-08-16 | reit | Benchmark | Buy → Buy | $8 |
| 2024-08-09 | reit | Benchmark | Buy → Buy | $8 |
| 2024-07-03 | reit | Benchmark | Buy → Buy | $8 |
| 2024-07-02 | reit | Benchmark | Buy → Buy | $8 |
| 2024-06-24 | reit | Benchmark | Buy → Buy | $8 |
| 2024-06-21 | reit | Benchmark | Buy → Buy | $8 |
| 2024-06-20 | main | Benchmark | Buy → Buy | $8 |
| 2024-04-11 | reit | Benchmark | Buy → Buy | $5 |
| 2024-03-07 | up | Benchmark | Hold → Buy | $5 |
News
RSS: Latest EBS news- Emergent BioSolutions Inc. (EBS) Stock Analysis: Navigating a 22.84% Potential Upside Amidst Healthcare Challenges - DirectorsTalk Interviews Fri, 20 Feb 2026 19
- $EBS stock is down 10% today. Here's what we see in our data. - Quiver Quantitative hu, 15 Jan 2026 08
- Emergent BioSolutions Inc.'s (NYSE:EBS) large institutional owners must be happy as stock continues to impress, up 10% over the past week - Yahoo Finance Fri, 26 Sep 2025 07
- Three AI Analyst Stocks, LSBK, EBS, and MNSO, Projected to Rise Over 20% - Intellectia AI Sat, 21 Feb 2026 02
- New NARCAN 6- and 24-packs approved to aid large-scale overdose preparedness - Stock Titan hu, 12 Feb 2026 23
- Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO - Stocktwits hu, 15 Jan 2026 22
- Emergent BioSolutions (EBS): Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results - simplywall.st Sun, 02 Nov 2025 07
- Emergent BioSolutions: Solid Q3, Expecting Better Days To Come - Seeking Alpha hu, 06 Nov 2025 08
- Trading Systems Reacting to (EBS) Volatility - Stock Traders Daily Wed, 18 Feb 2026 08
- Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS) - Yahoo Finance Fri, 07 Nov 2025 08
- $EBS stock is up 30% today. Here's what we see in our data. - Quiver Quantitative hu, 30 Oct 2025 07
- Emergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site - Stock Titan Fri, 12 Dec 2025 08
- Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership - simplywall.st Sat, 20 Dec 2025 08
- Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 23% Upside Potential and Robust Free Cash Flow - DirectorsTalk Interviews Fri, 16 Jan 2026 08
- Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance Fri, 31 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 21984 | 263077 | — | Sale at price 11.90 - 12.11 per share. | RICHARD RONALD B | Director | — | 2025-12-05 00:00:00 | D |
| 1 | 25748 | 129255 | — | Conversion of Exercise of derivative security at price 5.02 per share. | RICHARD RONALD B | Director | — | 2025-12-05 00:00:00 | D |
| 2 | 17801 | 187623 | — | Sale at price 10.54 per share. | DEGOLYER DONALD W | Director | — | 2025-11-10 00:00:00 | D |
| 3 | 8552 | 85520 | — | Sale at price 10.00 per share. | DAYAL SUJATA TYAGI | Director | — | 2025-11-07 00:00:00 | D |
| 4 | 30608 | 306080 | — | Sale at price 10.00 per share. | GLESSNER COLEEN | Officer | — | 2025-10-07 00:00:00 | D |
| 5 | 7086 | 62853 | — | Sale at price 8.87 per share. | ZOON KATHRYN C. | Director | — | 2025-08-15 00:00:00 | D |
| 6 | 7844 | 67831 | — | Sale at price 8.65 per share. | DEGOLYER DONALD W | Director | — | 2025-08-12 00:00:00 | D |
| 7 | 7844 | 49417 | — | Sale at price 6.30 per share. | KATKIN KEITH A | Director | — | 2025-05-23 00:00:00 | D |
| 8 | 60000 | 349800 | — | Purchase at price 5.83 per share. | PAPA JOSEPH C | Chief Executive Officer | — | 2025-05-13 00:00:00 | D |
| 9 | 34403 | — | — | Stock Award(Grant) at price 0.00 per share. | RICHARD RONALD B | Director | — | 2025-04-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -609.00K | -94.65M | -201.00K | -11.68M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.03 | 0.28 |
| NormalizedEBITDA | 39.80M | -67.50M | -31.70M | 503.20M |
| TotalUnusualItems | -2.90M | -450.70M | -6.70M | -41.70M |
| TotalUnusualItemsExcludingGoodwill | -2.90M | -450.70M | -6.70M | -41.70M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -190.60M | -760.50M | -211.60M | 219.50M |
| ReconciledDepreciation | 108.80M | 125.10M | 143.30M | 123.80M |
| ReconciledCostOfRevenue | 637.60M | 645.90M | 609.70M | 682.80M |
| EBITDA | 36.90M | -518.20M | -38.40M | 461.50M |
| EBIT | -71.90M | -643.30M | -181.70M | 337.70M |
| NetInterestIncome | -71.00M | -87.90M | -37.30M | -34.50M |
| InterestExpense | 71.00M | 87.90M | 37.30M | 34.50M |
| NormalizedIncome | -188.31M | -404.45M | -205.10M | 249.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -190.60M | -760.50M | -211.60M | 219.50M |
| TotalExpenses | 1.10B | 1.22B | 1.24B | 1.26B |
| TotalOperatingIncomeAsReported | -108.70M | -726.40M | -170.00M | 341.40M |
| DilutedAverageShares | 53.00M | 51.20M | 50.10M | 54.10M |
| BasicAverageShares | 53.00M | 51.20M | 50.10M | 53.50M |
| DilutedEPS | -3.60 | -14.85 | -4.47 | 4.27 |
| BasicEPS | -3.60 | -14.85 | -4.47 | 4.32 |
| DilutedNIAvailtoComStockholders | -190.60M | -760.50M | -211.60M | 219.50M |
| NetIncomeCommonStockholders | -190.60M | -760.50M | -211.60M | 219.50M |
| NetIncome | -190.60M | -760.50M | -211.60M | 219.50M |
| NetIncomeIncludingNoncontrollingInterests | -190.60M | -760.50M | -211.60M | 219.50M |
| NetIncomeContinuousOperations | -190.60M | -760.50M | -211.60M | 219.50M |
| TaxProvision | 47.70M | 29.30M | -7.40M | 83.70M |
| PretaxIncome | -142.90M | -731.20M | -219.00M | 303.20M |
| OtherIncomeExpense | 9.60M | -441.80M | -18.40M | -45.40M |
| OtherNonOperatingIncomeExpenses | 12.50M | 8.90M | -11.70M | -3.70M |
| SpecialIncomeCharges | -2.90M | -450.70M | -6.70M | -41.70M |
| GainOnSaleOfBusiness | 24.30M | 74.20M | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 27.20M | 524.90M | 6.70M | 41.70M |
| NetNonOperatingInterestIncomeExpense | -71.00M | -87.90M | -37.30M | -34.50M |
| InterestExpenseNonOperating | 71.00M | 87.90M | 37.30M | 34.50M |
| OperatingIncome | -81.50M | -201.50M | -163.30M | 383.10M |
| OperatingExpense | 413.80M | 519.10M | 546.30M | 508.20M |
| OtherOperatingExpenses | -30.00M | -26.30M | -41.40M | -134.20M |
| DepreciationAmortizationDepletionIncomeStatement | 65.10M | 65.60M | 59.90M | 58.50M |
| DepreciationAndAmortizationInIncomeStatement | 65.10M | 65.60M | 59.90M | 58.50M |
| Amortization | 65.10M | 65.60M | 59.90M | 58.50M |
| AmortizationOfIntangiblesIncomeStatement | 65.10M | 65.60M | 59.90M | 58.50M |
| ResearchAndDevelopment | 70.70M | 111.40M | 188.30M | 235.20M |
| SellingGeneralAndAdministration | 308.00M | 368.40M | 339.50M | 348.70M |
| GrossProfit | 332.30M | 317.60M | 383.00M | 891.30M |
| CostOfRevenue | 681.30M | 705.40M | 693.10M | 748.10M |
| TotalRevenue | 1.01B | 1.02B | 1.08B | 1.64B |
| OperatingRevenue | 1.01B | 1.02B | 1.08B | 1.64B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 5.60M | 5.60M | 5.60M | 3.80M |
| OrdinarySharesNumber | 54.33M | 52.20M | 50.10M | 51.30M |
| ShareIssued | 59.93M | 57.80M | 55.70M | 55.10M |
| NetDebt | 564.20M | 748.50M | 763.20M | 264.90M |
| TotalDebt | 663.70M | 860.20M | 1.41B | 841.00M |
| TangibleBookValue | -18.70M | 82.70M | 440.70M | 782.00M |
| InvestedCapital | 1.15B | 1.51B | 2.79B | 2.45B |
| WorkingCapital | 436.30M | 28.20M | -18.50M | 895.90M |
| NetTangibleAssets | -18.70M | 82.70M | 440.70M | 782.00M |
| CommonStockEquity | 482.80M | 649.30M | 1.39B | 1.61B |
| TotalCapitalization | 1.15B | 1.10B | 1.84B | 2.42B |
| TotalEquityGrossMinorityInterest | 482.80M | 649.30M | 1.39B | 1.61B |
| StockholdersEquity | 482.80M | 649.30M | 1.39B | 1.61B |
| GainsLossesNotAffectingRetainedEarnings | -5.20M | -5.70M | 3.10M | -16.10M |
| OtherEquityAdjustments | -5.20M | -5.70M | 3.10M | -16.10M |
| TreasuryStock | 227.70M | 227.70M | 227.70M | 152.20M |
| RetainedEarnings | -212.40M | -21.80M | 738.70M | 950.30M |
| AdditionalPaidInCapital | 928.00M | 904.40M | 873.50M | 829.40M |
| CapitalStock | 100.00K | 100.00K | 100.00K | 100.00K |
| CommonStock | 100.00K | 100.00K | 100.00K | 100.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 906.90M | 1.17B | 1.78B | 1.35B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 744.50M | 522.60M | 549.70M | 972.20M |
| OtherNonCurrentLiabilities | 39.10M | 28.90M | 41.50M | 69.50M |
| NonCurrentDeferredLiabilities | 41.70M | 47.20M | 59.70M | 93.30M |
| NonCurrentDeferredRevenue | 4.70M | |||
| NonCurrentDeferredTaxesLiabilities | 41.70M | 47.20M | 59.70M | 93.30M |
| LongTermDebtAndCapitalLeaseObligation | 663.70M | 446.50M | 448.50M | 809.40M |
| LongTermDebt | 663.70M | 446.50M | 448.50M | 809.40M |
| CurrentLiabilities | 162.40M | 651.30M | 1.23B | 374.00M |
| OtherCurrentLiabilities | 27.70M | 32.70M | 45.90M | 73.10M |
| CurrentDebtAndCapitalLeaseObligation | 413.70M | 957.30M | 31.60M | |
| CurrentDebt | 413.70M | 957.30M | 31.60M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 56.10M | 74.10M | 87.30M | 88.70M |
| PayablesAndAccruedExpenses | 78.60M | 130.80M | 138.40M | 180.60M |
| CurrentAccruedExpenses | 17.70M | 18.60M | 34.90M | 51.70M |
| Payables | 60.90M | 112.20M | 103.50M | 128.90M |
| AccountsPayable | 60.90M | 112.20M | 103.50M | 128.90M |
| TotalAssets | 1.39B | 1.82B | 3.17B | 2.96B |
| TotalNonCurrentAssets | 791.00M | 1.14B | 1.96B | 1.69B |
| OtherNonCurrentAssets | 18.90M | 194.30M | 191.30M | 58.20M |
| GoodwillAndOtherIntangibleAssets | 501.50M | 566.60M | 947.00M | 829.50M |
| OtherIntangibleAssets | 501.50M | 566.60M | 728.80M | 604.60M |
| Goodwill | 0.00 | 218.20M | 224.90M | |
| NetPPE | 270.60M | 382.80M | 817.60M | 800.10M |
| AccumulatedDepreciation | -397.10M | -411.40M | -383.80M | -319.10M |
| GrossPPE | 667.70M | 794.20M | 1.20B | 1.12B |
| ConstructionInProgress | 10.30M | 36.70M | 185.50M | 223.20M |
| MachineryFurnitureEquipment | 435.50M | 497.60M | 633.10M | 574.20M |
| BuildingsAndImprovements | 196.10M | 229.90M | 327.90M | 269.70M |
| LandAndImprovements | 25.80M | 30.00M | 54.90M | 52.10M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 598.70M | 679.50M | 1.21B | 1.27B |
| OtherCurrentAssets | 26.90M | 47.90M | 57.90M | 70.20M |
| RestrictedCash | 6.10M | 0.00 | 0.00 | 200.00K |
| PrepaidAssets | 70.30M | |||
| Inventory | 311.70M | 328.90M | 350.70M | 344.50M |
| FinishedGoods | 129.50M | 86.90M | 92.20M | 35.90M |
| WorkInProcess | 86.30M | 113.30M | 116.20M | 95.80M |
| RawMaterials | 95.90M | 128.70M | 142.30M | 212.80M |
| Receivables | 154.50M | 191.00M | 159.20M | 278.90M |
| ReceivablesAdjustmentsAllowances | -500.00K | -2.20M | -700.00K | -3.20M |
| OtherReceivables | 19.60M | 51.40M | 57.20M | 51.60M |
| AccountsReceivable | 135.40M | 141.80M | 102.70M | 230.50M |
| AllowanceForDoubtfulAccountsReceivable | -700.00K | -3.20M | ||
| GrossAccountsReceivable | 135.40M | 141.80M | 102.70M | 230.50M |
| CashCashEquivalentsAndShortTermInvestments | 99.50M | 111.70M | 642.60M | 576.10M |
| CashAndCashEquivalents | 99.50M | 111.70M | 642.60M | 576.10M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 35.80M | -257.90M | -149.90M | 96.10M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -82.10M | -106.00M |
| RepaymentOfDebt | -482.40M | -563.40M | -33.80M | -35.90M |
| IssuanceOfDebt | 284.00M | 20.00M | 598.00M | 0.00 |
| IssuanceOfCapitalStock | 9.30M | 8.40M | 0.00 | 0.00 |
| CapitalExpenditure | -22.90M | -51.60M | -115.80M | -224.10M |
| InterestPaidSupplementalData | 64.00M | 68.30M | 33.00M | 30.40M |
| IncomeTaxPaidSupplementalData | 26.50M | 52.80M | 6.20M | 71.60M |
| EndCashPosition | 105.60M | 111.70M | 642.60M | 576.30M |
| BeginningCashPosition | 111.70M | 642.60M | 576.30M | 621.50M |
| EffectOfExchangeRateChanges | 0.00 | -1.20M | 500.00K | -300.00K |
| ChangesInCash | -6.10M | -529.70M | 65.80M | -44.90M |
| FinancingCashFlow | -190.00M | -535.70M | 481.20M | -141.00M |
| CashFlowFromContinuingFinancingActivities | -190.00M | -535.70M | 481.20M | -141.00M |
| NetOtherFinancingCharges | -15.80M | -2.50M | -5.90M | -15.00M |
| ProceedsFromStockOptionExercised | 14.90M | 1.80M | 5.00M | 15.90M |
| NetCommonStockIssuance | 9.30M | 8.40M | -82.10M | -106.00M |
| CommonStockPayments | 0.00 | 0.00 | -82.10M | -106.00M |
| CommonStockIssuance | 9.30M | 8.40M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -198.40M | -543.40M | 564.20M | -35.90M |
| NetShortTermDebtIssuance | 598.00M | 0.00 | ||
| ShortTermDebtPayments | 0.00 | 0.00 | ||
| ShortTermDebtIssuance | 598.00M | 0.00 | ||
| NetLongTermDebtIssuance | -198.40M | -543.40M | 564.20M | -35.90M |
| LongTermDebtPayments | -482.40M | -563.40M | -33.80M | -35.90M |
| LongTermDebtIssuance | 284.00M | 20.00M | 598.00M | 0.00 |
| InvestingCashFlow | 125.20M | 212.30M | -381.30M | -224.10M |
| CashFlowFromContinuingInvestingActivities | 125.20M | 212.30M | -381.30M | -224.10M |
| NetOtherInvestingChanges | 30.00M | -6.30M | -265.50M | |
| NetBusinessPurchaseAndSale | 110.20M | 270.20M | 0.00 | 0.00 |
| SaleOfBusiness | 110.20M | 270.20M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | -21.80M | 0.00 | ||
| PurchaseOfIntangibles | -21.80M | 0.00 | ||
| NetPPEPurchaseAndSale | -15.00M | -51.60M | -115.80M | -224.10M |
| SaleOfPPE | 7.90M | 0.00 | 0.00 | |
| PurchaseOfPPE | -22.90M | -51.60M | -115.80M | -224.10M |
| OperatingCashFlow | 58.70M | -206.30M | -34.10M | 320.20M |
| CashFlowFromContinuingOperatingActivities | 58.70M | -206.30M | -34.10M | 320.20M |
| ChangeInWorkingCapital | 88.70M | -70.30M | -2.10M | -145.00M |
| ChangeInOtherWorkingCapital | 6.60M | -5.50M | 38.30M | -63.10M |
| ChangeInPayablesAndAccruedExpense | -38.90M | -55.50M | -81.50M | -6.80M |
| ChangeInAccruedExpense | -5.90M | -66.10M | -67.50M | -5.20M |
| ChangeInPayable | -33.00M | 10.60M | -14.00M | -1.60M |
| ChangeInAccountPayable | -33.00M | 10.60M | -14.00M | -1.60M |
| ChangeInPrepaidAssets | 169.90M | 11.70M | -19.90M | 7.70M |
| ChangeInInventory | -24.50M | 600.00K | -57.10M | -66.60M |
| ChangeInReceivables | -24.40M | -21.60M | 118.10M | -16.20M |
| ChangesInAccountReceivables | -24.40M | -21.60M | 118.10M | -16.20M |
| OtherNonCashItems | 14.50M | 13.40M | 9.50M | 9.00M |
| StockBasedCompensation | 18.00M | 23.10M | 45.10M | 42.40M |
| AssetImpairmentCharge | 27.20M | 524.90M | 6.70M | 24.50M |
| DeferredTax | -5.50M | -8.90M | -28.60M | 46.00M |
| DeferredIncomeTax | -5.50M | -8.90M | -28.60M | 46.00M |
| DepreciationAmortizationDepletion | 108.80M | 125.10M | 143.30M | 123.80M |
| DepreciationAndAmortization | 108.80M | 125.10M | 143.30M | 123.80M |
| AmortizationCashFlow | 65.10M | 65.60M | 59.90M | |
| AmortizationOfIntangibles | 65.10M | 65.60M | 59.90M | |
| Depreciation | 43.70M | 59.50M | 83.40M | |
| OperatingGainsLosses | -2.40M | -53.10M | 3.60M | |
| GainLossOnInvestmentSecurities | 1.10M | |||
| GainLossOnSaleOfBusiness | -32.20M | -74.20M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -190.60M | -760.50M | -211.60M | 219.50M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EBS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|